Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages

  Iannone, Florenzo ^a   Ferraccioli, Gianfranco ^b   Gremese, Elisa ^b   Lapadula, Giovanni ^a  

^a UNIVERSITY OF BARI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL DECISION MAKING; COHORT ANALYSIS; FOLLOW UP; HUMAN; ITALY; LETTER; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SURVIVAL RATE; TREATMENT OUTCOME;

ANTI-TNF; RHEUMATOID ARTHRITIS; TNF-ALPHA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN G; MEDICATION ADHERENCE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899917627     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-205011     Document Type: Letter

References (3)

1. Neovius M, Arkema EV, Olsson H, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. Published Online First 27 Nov 2013. doi:10.1136/annrheumdis-2013-204128
2. Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008;67: 1229-34.
3. Iannone F, Gremese E, Atzeni F, et al. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 2012;39: 1179-84.